Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy PS Dragovich, TH Pillow, RA Blake, JD Sadowsky, E Adaligil, P Adhikari, ... Journal of Medicinal Chemistry 64 (5), 2576-2607, 2021 | 94 | 2021 |
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy Z Li, GR Mirams, T Yoshinaga, BJ Ridder, X Han, JE Chen, ... Clinical Pharmacology & Therapeutics 107 (1), 102-111, 2020 | 75 | 2020 |
Drug‐induced allergic hepatitis develops in mice when myeloid‐derived suppressor cells are depleted prior to halothane treatment M Chakraborty, AM Fullerton, K Semple, LS Chea, WR Proctor, M Bourdi, ... Hepatology 62 (2), 546-557, 2015 | 60 | 2015 |
Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction KM Beggs, AM Fullerton, K Miyakawa, PE Ganey, RA Roth toxicological sciences 137 (1), 91-101, 2014 | 44 | 2014 |
Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis CM Dugan, AM Fullerton, RA Roth, PE Ganey Toxicological Sciences 120 (2), 507-518, 2011 | 39 | 2011 |
Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate) SW Baran, PC Brown, AR Baudy, SC Fitzpatrick, C Frantz, A Fullerton, ... ALTEX-Alternatives to animal experimentation 39 (2), 297-314, 2022 | 36 | 2022 |
The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability PJ Shaw, AM Fullerton, MA Scott, PE Ganey, RA Roth Toxicology and applied pharmacology 236 (3), 293-300, 2009 | 33 | 2009 |
Application of microphysiological systems in biopharmaceutical research and development NC Peterson, PK Mahalingaiah, A Fullerton, M Di Piazza Lab on a Chip 20 (4), 697-708, 2020 | 30 | 2020 |
Safety lead optimization and candidate identification: integrating new technologies into decision-making DM Dambach, D Misner, M Brock, A Fullerton, W Proctor, J Maher, D Lee, ... Chemical research in toxicology 29 (4), 452-472, 2016 | 29 | 2016 |
Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia … KM Beggs, AR Maiuri, AM Fullerton, KL Poulsen, AB Breier, PE Ganey, ... Toxicology 331, 35-46, 2015 | 24 | 2015 |
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma S Kakiuchi-Kiyota, T Ross, HA Wallweber, JR Kiefer, MM Schutten, ... Leukemia 36 (4), 1006-1014, 2022 | 22 | 2022 |
Thymic stromal lymphopoietin and interleukin‐4 mediate the pathogenesis of halothane‐induced liver injury in mice WR Proctor, M Chakraborty, AM Fullerton, MC Korrapati, PM Ryan, ... Hepatology 60 (5), 1741-1752, 2014 | 22 | 2014 |
Pretreatment with TCDD exacerbates liver injury from Concanavalin A: critical role for NK cells AM Fullerton, RA Roth, PE Ganey toxicological sciences 136 (1), 72-85, 2013 | 17 | 2013 |
2, 3, 7, 8-TCDD enhances the sensitivity of mice to concanavalin A immune-mediated liver injury AM Fullerton, RA Roth, PE Ganey Toxicology and applied pharmacology 266 (2), 317-327, 2013 | 14 | 2013 |
Inflammation and hepatotoxicity JP Luyendyk, PE Ganey, A Fullerton, RA Roth Elsevier, 2018 | 12 | 2018 |
Proof of concept for an automated image analysis method to quantify rat bone marrow hematopoietic lineages on H&E sections C Kozlowski, A Fullerton, G Cain, P Katavolos, J Bravo, JM Tarrant Toxicologic Pathology 46 (3), 336-347, 2018 | 10 | 2018 |
Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma S Kakiuchi-Kiyota, MM Schutten, AO Adedeji, H Cai, R Hendricks, L Liu, ... Cancer Res 80 (16Supplement), 4556, 2020 | 9 | 2020 |
Reversible covalent inhibition of a phenol sulfotransferase by coenzyme A S Chodavarapu, H Hertema, T Huynh, J Odette, R Miller, A Fullerton, ... Archives of biochemistry and biophysics 457 (2), 197-204, 2007 | 8 | 2007 |
Towards in vitro models for reducing or replacing the use of animals in drug testing DM Stresser, AK Kopec, P Hewitt, RN Hardwick, TR Van Vleet, ... Nature Biomedical Engineering, 1-6, 2023 | 5 | 2023 |
In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk LM Norona, A Fullerton, C Lawson, L Leung, J Brumm, T Kiyota, J Maher, ... Archives of Toxicology 94, 3185-3200, 2020 | 5 | 2020 |